RxDoctor Payments Data

Nancy Neighbors, MD

Family Medicine · Huntsville, ALNPI 1689623795

Payments from drug & device makers

$8,197in general payments, 2019–2025

Across 465 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AbbVie$859
  • GSK$627
  • Lilly USA, LLC$529
  • Amgen$371
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$320
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$8,186100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,197 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$2,608
Medicare patients
13
Services billed
149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide47$60,792
OzempicSemaglutide51$48,426
JardianceEmpagliflozin58$35,617
EliquisApixaban31$27,001
CreonLipase/Protease/Amylase11$25,599
RybelsusSemaglutide19$20,075
XareltoRivaroxaban24$17,969
TrulicityDulaglutide13$14,261
MyrbetriqMirabegron17$12,577
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$12,017
Breo ElliptaFluticasone/Vilanterol25$9,553
GemtesaVibegron19$8,239
Tresiba Flextouch U-200Insulin Degludec11$6,489
XyostedTestosterone Enanthate11$6,460
Spiriva RespimatTiotropium Bromide13$6,449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$529$75,05260 claims
Novo NordiskOzempic, Rybelsus$3,088$68,50170 claims
Boehringer IngelheimJardiance, Spiriva Respimat$39$42,06671 claims
AbbVieCreon, Linzess$859$31,31622 claims
PfizerEliquis$165$27,00131 claims
GSKTrelegy Ellipta, Breo Ellipta$627$21,56941 claims
Johnson & JohnsonXarelto$71$17,96924 claims
Astellas Pharma US IncMyrbetriq$100$12,57717 claims
Sumitomo Pharma America, Inc.Gemtesa$116$8,23919 claims
Antares Pharma, Inc.Xyosted$18$6,46011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →